AgingResearch.NewsJoin free

Revolution Medicines

CompanyUnited StatesFounded 2014

Wikidata

Revolution Medicines develops 2 assets, the furthest in phase 3 (daraxonrasib in metastatic RAS G12D pancreatic adenocarcinoma). Mostly other and small molecule acting on KRAS, NRAS and HRAS; based in the United States, founded in 2014.

2
Assets
Furthest stage
Phase 3
5
Trials
0
Signals

Pipeline

2

  • daraxonrasib

    RAS(ON) multi-selective inhibitor

    Phase 3, Other, KRAS, NRAS, metastatic RAS G12D pancreatic adenocarcinoma, metastatic RAS G12D pancreatic cancer

  • zoldonrasib

    RAS(ON) G12D-selective inhibitor

    Phase 3, Small molecule, KRAS, metastatic RAS G12D pancreatic adenocarcinoma, metastatic RAS G12D pancreatic cancer

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms3
  • Trials5
  • Similar companies6

Intelligence